New Delhi, August 13, 2026: India’s pharmaceutical exports rose 6.8% year-on-year to $8.1 billion in the first quarter of FY 2026-27 (Q1 FY27), signalling continued global demand for Indian medicines, pharmaceutical formulations, bulk drugs, vaccines and surgical products.
According to data released by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), pharmaceutical exports stood at $7.58 billion in April-June FY26. The latest Q1 FY27 performance represents an increase of about $520 million over the corresponding quarter of the previous financial year. The data underscores the resilience of India’s pharmaceutical export sector amid changing global trade and regulatory conditions.
India Pharma Exports Rise to $8.1 Billion in Q1 FY27
The growth was supported by strong shipments across several pharmaceutical product categories. In June 2026 alone, India’s pharmaceutical exports increased 7.13% to $2.81 billion, compared with $2.62 billion in June 2025. June exports were also 6.86% higher than the $2.63 billion recorded in May 2026.
The latest figures indicate that export momentum strengthened towards the end of the quarter, with demand remaining firm across established markets as well as several emerging destinations.
Drug Formulations and Biologicals Remain the Largest Export Segment
Drug formulations and biologicals continued to dominate India’s pharmaceutical export basket during Q1 FY27. The segment generated $5.98 billion, accounting for approximately 73.85% of total pharmaceutical exports. It registered growth of 4.14% compared with the same quarter of FY26.
Bulk drugs and drug intermediates recorded stronger expansion, increasing 13.84% to $1.36 billion. The performance points to continued international demand for Indian pharmaceutical ingredients and intermediate products.
Vaccine exports posted particularly strong growth, rising 35.68% to $0.39 billion. Exports of surgical products increased 11.95% to $0.21 billion during the quarter.
| Pharmaceutical Segment | Q1 FY27 Exports | YoY Growth |
|---|---|---|
| Drug formulations & biologicals | $5.98 billion | 4.14% |
| Bulk drugs & intermediates | $1.36 billion | 13.84% |
| Vaccines | $0.39 billion | 35.68% |
| Surgical products | $0.21 billion | 11.95% |
United States Remains India’s Largest Pharma Export Market
The United States remained the largest destination for Indian pharmaceutical exports during April-June FY27. Shipments to the US were valued at approximately $2.50 billion, representing a 30.89% share of India’s pharmaceutical exports during the quarter.
Brazil, the United Kingdom, the Netherlands and France were among the other leading export destinations. The top 25 destinations together accounted for nearly 70% of India’s pharmaceutical exports, with shipments valued at about $5.65 billion. Exports to these markets increased 5.50% year-on-year during Q1 FY27.
At the regional level, NAFTA, Europe, Africa and Latin America and the Caribbean (LAC) collectively accounted for nearly three-fourths of India’s pharmaceutical exports. NAFTA alone represented 34.28% of total pharmaceutical exports.
Export Growth Shows Wider Geographic Diversification
The Q1 FY27 figures point to a combination of strong demand in established markets and increasing opportunities across emerging economies. Pharmexcil Chairman Namit Joshi said the sector was combining scale in established markets with growing momentum across a wider range of geographies.
According to Pharmexcil, double-digit growth across parts of Europe, Africa, Latin America, ASEAN and South Asia is significant for India as global pharmaceutical supply chains adjust to changing trade conditions.
The diversification trend is strategically important because the United States remains a critical market for Indian pharmaceutical exporters. Wider market penetration can help companies reduce concentration risk while creating additional opportunities for higher-value pharmaceutical products.
India Targets $50 Billion in Pharma Exports by 2030
The Q1 FY27 performance comes as India seeks to raise pharmaceutical exports substantially over the remainder of the decade. Government data presented in June 2026 showed that pharmaceutical exports increased from about $14 billion in FY2014-15 to around $31 billion in FY2025-26.
The Government of India has set an objective of achieving approximately $50 billion in pharmaceutical exports by 2030, with policy emphasis on quality, innovation, regulatory excellence and market diversification.
The government has also highlighted India’s transition from predominantly volume-driven exports towards greater value creation through advanced pharmaceutical products, innovation, manufacturing capabilities and deeper participation in global healthcare supply chains.
Focus Shifts Towards Complex Generics, Biosimilars and Advanced Products
Industry stakeholders believe the next phase of India’s pharmaceutical export growth will increasingly depend on higher-value segments. These include complex generics, biosimilars, peptides and other innovation-led pharmaceutical products.
Pharmexcil has also stressed the need for greater investment in advanced manufacturing, stronger quality systems, specialised production capabilities and regulatory preparedness. Strengthening the capabilities of Indian pharmaceutical MSMEs is expected to remain important for expanding participation in both regulated and emerging international markets.
The strong increase in vaccine exports during Q1 FY27 is also noteworthy. The 35.68% rise demonstrates the potential of India’s broader pharmaceutical manufacturing base beyond traditional generic formulations.
What the Q1 FY27 Pharma Export Numbers Mean for India
India’s $8.1 billion pharmaceutical exports in Q1 FY27 provide a positive start to the new financial year. The 6.8% year-on-year increase reflects continued international demand, while stronger growth in vaccines, bulk drugs and surgical products points to diversification within the export basket.
For Indian pharmaceutical companies, the immediate opportunity lies in expanding market access while maintaining strict quality and regulatory compliance. Over the longer term, the ability to move towards complex, specialised and innovation-driven products will be critical for improving export value and supporting the government’s $50 billion target.
With pharmaceutical exports already at around $31 billion in FY26, the Q1 FY27 performance indicates that India remains firmly positioned as a major supplier in global pharmaceutical markets. Sustained investment in manufacturing, regulatory capabilities, product development and geographic diversification will determine whether the sector can maintain this momentum through FY27 and beyond.
Key Takeaways
• India’s pharmaceutical exports reached $8.1 billion in Q1 FY27, up 6.8% from $7.58 billion in Q1 FY26.
• Drug formulations and biologicals accounted for $5.98 billion, or 73.85% of total exports.
• Bulk drugs and intermediates grew 13.84% to $1.36 billion.
• Vaccine exports increased 35.68% to $0.39 billion.
• The US remained the largest destination, with $2.50 billion of exports and a 30.89% share.
• NAFTA, Europe, Africa and LAC together accounted for nearly 75% of exports.
• India is targeting approximately $50 billion in pharmaceutical exports by 2030.
Sources
Data in this report is based principally on figures attributed to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), as reported on August 12, 2026 by Express Pharma.
Government policy and long-term export targets have been cross-checked against the Press Information Bureau, Ministry of Commerce & Industry and related government communications on India’s pharmaceutical export strategy.
News updated as of August 13, 2026. Figures are reported in US dollars unless otherwise stated.